{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:12:48Z","timestamp":1793308368858,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01560-5","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:10:53Z","timestamp":1785946253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"9742","key":"1560_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"3","key":"1560_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476\u201384.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1560_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","volume":"140","author":"AN Bartley","year":"2016","unstructured":"Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline recommendations from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345\u201363.","journal-title":"Arch Pathol Lab Med"},{"issue":"7517","key":"1560_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"key":"1560_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Gastric Cancer. Version 2.2025. National Comprehensive Cancer Network; 2025."},{"key":"1560_CR6","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.5230\/jgc.2025.25.e10","volume":"25","author":"SS Eom","year":"2025","unstructured":"Eom SS, Ryu MH, Park SR, et al. Korean practice guidelines for gastric cancer 2024 update: systemic treatment. J Gastric Cancer. 2025;25:e10.","journal-title":"J Gastric Cancer"},{"issue":"11","key":"1560_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomized, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"10389","key":"1560_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT). Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"8","key":"1560_CR9","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"5","key":"1560_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma: the TRIO-013\/LOGiC trial. J Clin Oncol. 2016;34(5):443\u201351.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1560_CR11","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","volume":"32","author":"T Satoh","year":"2014","unstructured":"Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN. J Clin Oncol. 2014;32(19):2039\u201349.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1560_CR12","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.2016.71.6852","volume":"35","author":"MA Shah","year":"2017","unstructured":"Shah MA, Xu RH, Bang YJ, et al. HELOISE: phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. J Clin Oncol. 2017;35(22):2558\u201367.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1560_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomized, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372\u201384.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1560_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1560_CR15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/cancers18091448","volume":"18","author":"JE Rogers","year":"2026","unstructured":"Rogers JE, Ajani JA. Bispecific antibodies and antibody-drug conjugates in advanced gastric adenocarcinoma. Cancers (Basel). 2026;18(9):1448.","journal-title":"Cancers (Basel)"},{"issue":"7890","key":"1560_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"issue":"10418","key":"1560_CR17","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomized placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"},{"issue":"suppl 2","key":"1560_CR18","first-page":"S1270","volume":"35","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Lonardi S, Shitara K, et al. Final overall survival for the phase 3 KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive advanced, unresectable or metastatic gastric\/gastroesophageal junction adenocarcinoma. Ann Oncol. 2024;35(suppl 2):S1270\u20131.","journal-title":"Ann Oncol"},{"issue":"10","key":"1560_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105542","volume":"10","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Kawazoe A, Xu J, et al. Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. ESMO Open. 2025;10(10):105542.","journal-title":"ESMO Open"},{"issue":"2","key":"1560_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/1078-0432.CCR-24-4295","volume":"32","author":"KW Lee","year":"2026","unstructured":"Lee KW, Bai LY, Jung M, et al. Phase Ib\/II study of zanidatamab in combination with tislelizumab and chemotherapy in first-line HER2-positive gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2026;32(2):312\u201323.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1560_CR21","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa2517729","volume":"394","author":"K Shitara","year":"2026","unstructured":"Shitara K, Elimova E, Bai LY, et al. Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer. N Engl J Med. 2026;394(20):2002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2517729.","journal-title":"N Engl J Med"},{"issue":"25","key":"1560_CR22","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"7","key":"1560_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02). Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"key":"1560_CR24","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.eclinm.2025.103404","volume":"87","author":"Z Peng","year":"2025","unstructured":"Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated HER2-positive locally advanced\/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. EClinicalMedicine. 2025;87:103404.","journal-title":"EClinicalMedicine"},{"key":"1560_CR25","volume":"11","author":"YY Janjigian","year":"2026","unstructured":"Janjigian YY, Smyth E, Shen L, et al. DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer. ESMO Open. 2026;11:100294.","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"1560_CR26","first-page":"TPS4204","volume":"43","author":"RH Xu","year":"2025","unstructured":"Xu RH, Janjigian YY, Shitara K, et al. ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan as first-line treatment for locally advanced or metastatic HER2-positive gastric cancer. J Clin Oncol. 2025;43(suppl 16):TPS4204.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1560_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106963","volume":"11","author":"CK Lee","year":"2026","unstructured":"Lee CK, Seo DH, Park S, et al. Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer. ESMO Open. 2026;11(5):106963.","journal-title":"ESMO Open"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01560-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01560-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01560-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:10:56Z","timestamp":1785946256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01560-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01560-5","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"177"}}